BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 10438376)

  • 1. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
    Gonczol E; Plotkin S
    Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
    Jacobson MA; Adler SP; Sinclair E; Black D; Smith A; Chu A; Moss RB; Wloch MK
    Vaccine; 2009 Mar; 27(10):1540-8. PubMed ID: 19168107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects.
    Schleiss MR; Bernstein DI; Passo M; Parker S; Meric C; Verdier F; Newkirk MM
    Vaccine; 2004 Dec; 23(5):687-92. PubMed ID: 15542191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
    Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
    Marshall BC; Adler SP
    Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
    Zhang C; Pass RF
    Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection.
    Schleiss MR; Bourne N; Bernstein DI
    J Infect Dis; 2003 Dec; 188(12):1868-74. PubMed ID: 14673766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
    Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
    J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus vaccine.
    Plotkin SA
    Am Heart J; 1999 Nov; 138(5 Pt 2):S484-7. PubMed ID: 10539854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.
    Axelsson F; Adler SP; Lamarre A; Ohlin M
    Vaccine; 2007 Dec; 26(1):41-6. PubMed ID: 18063447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
    Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
    Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.
    Bernstein DI; Reap EA; Katen K; Watson A; Smith K; Norberg P; Olmsted RA; Hoeper A; Morris J; Negri S; Maughan MF; Chulay JD
    Vaccine; 2009 Dec; 28(2):484-93. PubMed ID: 19857446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.